FGFR1 and neoplasm: For example, Shi et al. (2020) established NSCLC organoids and utilized transcriptomics analysis, revealing that the combination of FGFR and MEK inhibitors showed better treatment effects than a single FGFR inhibitor in FGFR1 amplified LUSC, which supports researchers’ earlier contention that PDOs can retain the targeted therapy sensitivity of its source tumor tissue.